BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li H, Sheng C, Wang S, Yang L, Liang Y, Huang Y, Liu H, Li P, Yang C, Yang X. Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9. Front Cell Infect Microbiol. 2017;7:91. [PMID: 28382278 DOI: 10.3389/fcimb.2017.00091] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 9.2] [Reference Citation Analysis]
Number Citing Articles
1 Tyagi S, Kumar R, Das A, Won SY, Shukla P. CRISPR-Cas9 system: A genome-editing tool with endless possibilities. Journal of Biotechnology 2020;319:36-53. [DOI: 10.1016/j.jbiotec.2020.05.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
2 Mohammadzadeh I, Qujeq D, Yousefi T, Ferns GA, Maniati M, Vaghari-Tabari M. CRISPR/Cas9 gene editing: A new therapeutic approach in the treatment of infection and autoimmunity. IUBMB Life. 2020;72:1603-1621. [PMID: 32344465 DOI: 10.1002/iub.2296] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
3 Kayesh MEH, Amako Y, Hashem MA, Murakami S, Ogawa S, Yamamoto N, Hifumi T, Miyoshi N, Sugiyama M, Tanaka Y, Mizokami M, Kohara M, Tsukiyama-Kohara K. Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNA. Virus Res 2020;290:198191. [PMID: 33049308 DOI: 10.1016/j.virusres.2020.198191] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
4 Gilani U, Shaukat M, Rasheed A, Shahid M, Tasneem F, Arshad M, Rashid N, Shahzad N. The implication of CRISPR/Cas9 genome editing technology in combating human oncoviruses. J Med Virol 2019;91:1-13. [PMID: 30133783 DOI: 10.1002/jmv.25292] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
5 Yang H, Chen P. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA. Virus Research 2018;244:304-10. [DOI: 10.1016/j.virusres.2017.06.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
6 Araldi RP, Khalil C, Grignet PH, Teixeira MR, de Melo TC, Módolo DG, Fernandes LGV, Ruiz J, de Souza EB. Medical applications of clustered regularly interspaced short palindromic repeats (CRISPR/Cas) tool: A comprehensive overview. Gene 2020;745:144636. [DOI: 10.1016/j.gene.2020.144636] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
7 Bhat MA, Bhat MA, Kumar V, Wani IA, Bashir H, Shah AA, Rahman S, Jan AT. The era of editing plant genomes using CRISPR/Cas: A critical appraisal. Journal of Biotechnology 2020;324:34-60. [DOI: 10.1016/j.jbiotec.2020.09.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Okoli A, Okeke MI, Tryland M, Moens U. CRISPR/Cas9-Advancing Orthopoxvirus Genome Editing for Vaccine and Vector Development. Viruses 2018;10:E50. [PMID: 29361752 DOI: 10.3390/v10010050] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
9 de Buhr H, Lebbink RJ. Harnessing CRISPR to combat human viral infections. Current Opinion in Immunology 2018;54:123-9. [DOI: 10.1016/j.coi.2018.06.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
10 Tang L, Kottilil S, Wilson E. Strategies to eliminate HBV infection: an update. Future Virology 2020;15:35-51. [DOI: 10.2217/fvl-2019-0133] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
11 Pandey M, Ojha D, Bansal S, Rode AB, Chawla G. From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases. Mol Aspects Med 2021;:101003. [PMID: 34332771 DOI: 10.1016/j.mam.2021.101003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Kirby EN, Shue B, Thomas PQ, Beard MR. CRISPR Tackles Emerging Viral Pathogens. Viruses 2021;13:2157. [PMID: 34834963 DOI: 10.3390/v13112157] [Reference Citation Analysis]
13 Bellizzi A, Ahye N, Jalagadugula G, Wollebo HS. A Broad Application of CRISPR Cas9 in Infectious Diseases of Central Nervous System. J Neuroimmune Pharmacol 2019;14:578-94. [PMID: 31512166 DOI: 10.1007/s11481-019-09878-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Koujah L, Shukla D, Naqvi AR. CRISPR-Cas based targeting of host and viral genes as an antiviral strategy. Semin Cell Dev Biol 2019;96:53-64. [PMID: 30953741 DOI: 10.1016/j.semcdb.2019.04.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
15 Zhang Y, Li M. Genome Editing Technologies as Cellular Defense Against Viral Pathogens. Front Cell Dev Biol 2021;9:716344. [PMID: 34336867 DOI: 10.3389/fcell.2021.716344] [Reference Citation Analysis]
16 Ernst MPT, Broeders M, Herrero-Hernandez P, Oussoren E, van der Ploeg AT, Pijnappel WWMP. Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease. Mol Ther Methods Clin Dev 2020;18:532-57. [PMID: 32775490 DOI: 10.1016/j.omtm.2020.06.022] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
17 Li H, Wang S, Dong X, Li Q, Li M, Li J, Guo Y, Jin X, Zhou Y, Song H, Kou Z. CRISPR-Cas13a Cleavage of Dengue Virus NS3 Gene Efficiently Inhibits Viral Replication. Mol Ther Nucleic Acids 2020;19:1460-9. [PMID: 32160714 DOI: 10.1016/j.omtn.2020.01.028] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
18 Ebrahimi S, Teimoori A, Khanbabaei H, Tabasi M. Harnessing CRISPR/Cas 9 System for manipulation of DNA virus genome. Rev Med Virol 2019;29:e2009. [PMID: 30260068 DOI: 10.1002/rmv.2009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
19 Sekiba K, Otsuka M, Ohno M, Yamagami M, Kishikawa T, Suzuki T, Ishibashi R, Seimiya T, Tanaka E, Koike K. Hepatitis B virus pathogenesis: Fresh insights into hepatitis B virus RNA. World J Gastroenterol 2018; 24(21): 2261-2268 [PMID: 29881235 DOI: 10.3748/wjg.v24.i21.2261] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
20 Ramalingam S, Thangavel S. CRISPR-Cas9 Probing of Infectious Diseases and Genetic Disorders. Indian J Pediatr 2019;86:1131-5. [PMID: 31367975 DOI: 10.1007/s12098-019-03037-9] [Reference Citation Analysis]
21 Chen S, Yu X, Guo D. CRISPR-Cas Targeting of Host Genes as an Antiviral Strategy. Viruses 2018;10:E40. [PMID: 29337866 DOI: 10.3390/v10010040] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
22 Song J, Zhang X, Ge Q, Yuan C, Chu L, Liang HF, Liao Z, Liu Q, Zhang Z, Zhang B. CRISPR/Cas9-mediated knockout of HBsAg inhibits proliferation and tumorigenicity of HBV-positive hepatocellular carcinoma cells. J Cell Biochem 2018;119:8419-31. [PMID: 29904948 DOI: 10.1002/jcb.27050] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
23 Li H, Sheng C, Liu H, Wang S, Zhao J, Yang L, Jia L, Li P, Wang L, Xie J, Xu D, Sun Y, Qiu S, Song H. Inhibition of HBV Expression in HBV Transgenic Mice Using AAV-Delivered CRISPR-SaCas9. Front Immunol. 2018;9:2080. [PMID: 30254645 DOI: 10.3389/fimmu.2018.02080] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
24 Gong Y, Bi Y, Li Z, Li Y, Yao Y, Long Q, Pu T, Chen C, Liu T, Dong S, Cun W. High-efficiency nonhomologous insertion of a foreign gene into the herpes simplex virus genome. J Gen Virol 2020;101:982-96. [PMID: 32602833 DOI: 10.1099/jgv.0.001451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Chen P, You L, Lu Y. Applications of CRISPR-Cas9 Technology in Translational Research on Solid-Tumor Cancers. CRISPR J 2018;1:47-54. [PMID: 31021191 DOI: 10.1089/crispr.2017.0001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
26 Demir E, Bilginer U, Balcioglu MS, Karsli T. Direct and indirect contributions of molecular genetics to farm animal welfare: a review. Anim Health Res Rev 2021;:1-10. [PMID: 34842522 DOI: 10.1017/S1466252321000104] [Reference Citation Analysis]
27 Lee C. CRISPR/Cas9-Based Antiviral Strategy: Current Status and the Potential Challenge. Molecules 2019;24:E1349. [PMID: 30959782 DOI: 10.3390/molecules24071349] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
28 Liu B, Saber A, Haisma HJ. CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment. Drug Discov Today 2019;24:955-70. [PMID: 30849442 DOI: 10.1016/j.drudis.2019.02.011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
29 Yao X, Li Z, Gong X, Fu X, Xiao X, He M, Huang B, Xu Z. Total saponins extracted from Abrus cantoniensis Hance suppress hepatitis B virus replication in vitro and in rAAV8-1.3HBV transfected mice. J Ethnopharmacol 2020;249:112366. [PMID: 31678415 DOI: 10.1016/j.jep.2019.112366] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
30 Strich JR, Chertow DS. CRISPR-Cas Biology and Its Application to Infectious Diseases. J Clin Microbiol 2019;57:e01307-18. [PMID: 30429256 DOI: 10.1128/JCM.01307-18] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
31 Stone D, Long KR, Loprieno MA, De Silva Feelixge HS, Kenkel EJ, Liley RM, Rapp S, Roychoudhury P, Nguyen T, Stensland L, Colón-Thillet R, Klouser LM, Weber ND, Le C, Wagoner J, Goecker EA, Li AZ, Eichholz K, Corey L, Tyrrell DL, Greninger AL, Huang ML, Polyak SJ, Aubert M, Sagartz JE, Jerome KR. CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice. Mol Ther Methods Clin Dev 2021;20:258-75. [PMID: 33473359 DOI: 10.1016/j.omtm.2020.11.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
32 Zhang S, Wang F, Zhang Z. Current advances in the elimination of hepatitis B in China by 2030. Front Med. 2017;11:490-501. [PMID: 29170919 DOI: 10.1007/s11684-017-0598-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
33 Xia Y, Liang TJ. Development of Direct-acting Antiviral and Host-targeting Agents for Treatment of Hepatitis B Virus Infection. Gastroenterology 2019;156:311-24. [PMID: 30243618 DOI: 10.1053/j.gastro.2018.07.057] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
34 Pan Q, Wang J, Gao Y, Cui H, Liu C, Qi X, Zhang Y, Wang Y, Wang X. The Natural Large Genomic Deletion Is Unrelated to the Increased Virulence of the Novel Genotype Fowl Adenovirus 4 Recently Emerged in China. Viruses 2018;10:E494. [PMID: 30217040 DOI: 10.3390/v10090494] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
35 Singh V, Gohil N, Ramírez García R, Braddick D, Fofié CK. Recent Advances in CRISPR-Cas9 Genome Editing Technology for Biological and Biomedical Investigations. J Cell Biochem 2018;119:81-94. [PMID: 28544016 DOI: 10.1002/jcb.26165] [Cited by in Crossref: 44] [Cited by in F6Publishing: 24] [Article Influence: 8.8] [Reference Citation Analysis]
36 Suzuki Y, Onuma H, Sato R, Sato Y, Hashiba A, Maeki M, Tokeshi M, Kayesh MEH, Kohara M, Tsukiyama-Kohara K, Harashima H. Lipid nanoparticles loaded with ribonucleoprotein-oligonucleotide complexes synthesized using a microfluidic device exhibit robust genome editing and hepatitis B virus inhibition. J Control Release 2021;330:61-71. [PMID: 33333121 DOI: 10.1016/j.jconrel.2020.12.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
37 Yang Y, Wang Q, Li Q, Men K, He Z, Deng H, Ji W, Wei Y. Recent Advances in Therapeutic Genome Editing in China. Hum Gene Ther 2018;29:136-45. [PMID: 29446996 DOI: 10.1089/hum.2017.210] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
38 Teng M, Yao Y, Nair V, Luo J. Latest Advances of Virology Research Using CRISPR/Cas9-Based Gene-Editing Technology and Its Application to Vaccine Development. Viruses 2021;13:779. [PMID: 33924851 DOI: 10.3390/v13050779] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
39 Lin H, Li G, Peng X, Deng A, Ye L, Shi L, Wang T, He J. The Use of CRISPR/Cas9 as a Tool to Study Human Infectious Viruses. Front Cell Infect Microbiol 2021;11:590989. [PMID: 34513721 DOI: 10.3389/fcimb.2021.590989] [Reference Citation Analysis]
40 Zhu A, Liao X, Li S, Zhao H, Chen L, Xu M, Duan X. HBV cccDNA and Its Potential as a Therapeutic Target. J Clin Transl Hepatol 2019;7:258-62. [PMID: 31608218 DOI: 10.14218/JCTH.2018.00054] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
41 Nidhi S, Anand U, Oleksak P, Tripathi P, Lal JA, Thomas G, Kuca K, Tripathi V. Novel CRISPR-Cas Systems: An Updated Review of the Current Achievements, Applications, and Future Research Perspectives. Int J Mol Sci 2021;22:3327. [PMID: 33805113 DOI: 10.3390/ijms22073327] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
42 Ghorbani A, Hadifar S, Salari R, Izadpanah K, Burmistrz M, Afsharifar A, Eskandari MH, Niazi A, Denes CE, Neely GG. A short overview of CRISPR-Cas technology and its application in viral disease control. Transgenic Res 2021;30:221-38. [PMID: 33830423 DOI: 10.1007/s11248-021-00247-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Zhang D, Zhang K, Protzer U, Zeng C. HBV Integration Induces Complex Interactions between Host and Viral Genomic Functions at the Insertion Site. J Clin Transl Hepatol 2021;9:399-408. [PMID: 34221926 DOI: 10.14218/JCTH.2021.00062] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Loesch R, Desbois-Mouthon C, Colnot S. Potentials of CRISPR in liver research and therapy. Clin Res Hepatol Gastroenterol 2019;43:5-11. [PMID: 29884474 DOI: 10.1016/j.clinre.2018.05.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
45 Lindh M, Rydell GE, Larsson SB. Impact of integrated viral DNA on the goal to clear hepatitis B surface antigen with different therapeutic strategies. Curr Opin Virol 2018;30:24-31. [PMID: 29453099 DOI: 10.1016/j.coviro.2018.01.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
46 Bloom K, Maepa MB, Ely A, Arbuthnot P. Gene Therapy for Chronic HBV-Can We Eliminate cccDNA? Genes (Basel) 2018;9:E207. [PMID: 29649127 DOI: 10.3390/genes9040207] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
47 Escalona-Noguero C, López-Valls M, Sot B. CRISPR/Cas technology as a promising weapon to combat viral infections. Bioessays 2021;43:e2000315. [PMID: 33569817 DOI: 10.1002/bies.202000315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Tang Y, Guo J, Wang T, Zhao K, Liu J, Gao J, Tian Z, An T, Cai X. CRISPR/Cas9‐mediated 2‐sgRNA cleavage facilitates Pseudorabies virus editing. FASEB j 2018;32:4293-301. [DOI: 10.1096/fj.201701129r] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
49 Xia Y, Guo H. Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential. Antiviral Res. 2020;180:104824. [PMID: 32450266 DOI: 10.1016/j.antiviral.2020.104824] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 9.5] [Reference Citation Analysis]
50 Mak L, Wong DK, Seto W, Lai C, Yuen MF. Hepatitis B core protein as a therapeutic target. Expert Opinion on Therapeutic Targets 2017;21:1153-9. [DOI: 10.1080/14728222.2017.1397134] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
51 Kong H, Ju E, Yi K, Xu W, Lao YH, Cheng D, Zhang Q, Tao Y, Li M, Ding J. Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma. Adv Sci (Weinh) 2021;:e2102051. [PMID: 34665528 DOI: 10.1002/advs.202102051] [Reference Citation Analysis]